{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:05:03Z","timestamp":1770494703598,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":225,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017192","name":"USC Norris Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["P30 CA014089"],"award-info":[{"award-number":["P30 CA014089"]}],"id":[{"id":"10.13039\/100017192","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ctarc.2023.100752","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T04:17:42Z","timestamp":1692332262000},"page":"100752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Real world prognostic utility of platelet lymphocyte ratio and nutritional status in first-line immunotherapy response in stage IV non-small cell lung cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"Madeline","family":"MacDonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darin","family":"Poei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Leyba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Diep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krithika","family":"Chennapan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge J.","family":"Nieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3957-6106","authenticated-orcid":false,"given":"Robert","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ctarc.2023.100752_bib0001","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","volume":"41","author":"Meng","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"10.1016\/j.ctarc.2023.100752_bib0002","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2023.100752_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106677","article-title":"Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"85","author":"Zhang","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.ctarc.2023.100752_bib0004","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2217\/imt-2020-0105","article-title":"Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy","volume":"12","author":"Kartolo","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ctarc.2023.100752_bib0005","article-title":"Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: a systematic review and meta-analysis","volume":"12","author":"Zhou","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2023.100752_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268288","article-title":"Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: a systematic review and meta-analysis","volume":"17","author":"Wang","year":"2022","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.ctarc.2023.100752_bib0007","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cll.2014.10.007","article-title":"White blood cell counts: reference methodology","volume":"35","author":"Chabot-Richards","year":"2015","journal-title":"Clin. Lab. Med."},{"key":"10.1016\/j.ctarc.2023.100752_bib0009","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2023.100752_bib0010","article-title":"Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers for advanced non-small-cell lung cancer treated with immunotherapy: a systematic review and meta-analysis","volume":"58","author":"Platini","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"8","key":"10.1016\/j.ctarc.2023.100752_bib0011","doi-asserted-by":"crossref","first-page":"e22964","DOI":"10.1002\/jcla.22964","article-title":"Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab","volume":"33","author":"Liu","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0013","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ccr.2013.05.008","article-title":"Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor","volume":"24","author":"Schumacher","year":"2013","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.ctarc.2023.100752_bib0014","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejim.2013.01.017","article-title":"The platelet-cancer loop","volume":"24","author":"Goubran","year":"2013","journal-title":"Eur. J. Intern. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0015","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.18632\/oncotarget.13714","article-title":"Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0016","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF01833352","article-title":"Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression","volume":"20","author":"Ariad","year":"1991","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.ctarc.2023.100752_bib0017","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4161\/mabs.2.2.11360","article-title":"The VEGF family in cancer and antibody-based strategies for their inhibition","volume":"2","author":"Sullivan","year":"2010","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0018","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1038\/s41467-021-27303-7","article-title":"Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer","volume":"12","author":"Hinterleitner","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0019","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40880-016-0170-7","article-title":"Effect of body mass index on survival of patients with stage I non-small cell lung cancer","volume":"36","author":"Xie","year":"2017","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.ctarc.2023.100752_bib0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.lungcan.2016.11.017","article-title":"Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC)","volume":"104","author":"Lam","year":"2017","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/1055-9965.EPI-15-1336","article-title":"Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials","volume":"26","author":"Greenlee","year":"2017","journal-title":"Cancer Epidemiol., Biomark. Prevent."},{"issue":"6","key":"10.1016\/j.ctarc.2023.100752_bib0022","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3892\/mco.2021.2410","article-title":"Lung cancer, treatment and nutritional status","volume":"15","author":"Pilikidou","year":"2021","journal-title":"Mol. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2023.100752_bib0023","doi-asserted-by":"crossref","first-page":"LMT26","DOI":"10.2217\/lmt-2019-0016","article-title":"Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer","volume":"9","author":"Gelibter","year":"2020","journal-title":"Lung Cancer Manag."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0024","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1186\/s12885-022-09744-5","article-title":"Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2023.100752_bib0025","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/01635581.2020.1769691","article-title":"The role of a cachexia grading system in patients with non-small cell lung cancer treated with immunotherapy: implications for survival","volume":"73","author":"Turcott","year":"2021","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.ctarc.2023.100752_bib0026","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"5","key":"10.1016\/j.ctarc.2023.100752_bib0027","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2023.100752_bib0028","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.21037\/tlcr-21-460","article-title":"Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors: results from a prospective, observational study","volume":"10","author":"Rounis","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"8","key":"10.1016\/j.ctarc.2023.100752_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8081211","article-title":"Nutrition in cancer patients","volume":"8","author":"Ravasco","year":"2019","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"Arends","year":"2017","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.ctarc.2023.100752_bib0031","unstructured":"Motulsky H.J. GraphPad prism 9 statistics guide - Kaplan-Meier (nonparametric) survival analysis. . https:\/\/www.graphpad.com\/guides\/prism\/latest\/statistics\/stat_kaplan-meier_survival_analysis.htm. Published 2023. Accessed Accessed May 22, 2023."},{"key":"10.1016\/j.ctarc.2023.100752_bib0032","unstructured":"Motulsky H.J. GraphPad prism 9 statistics guide - cox regression (Cox proportional hazards model). . https:\/\/www.graphpad.com\/guides\/prism\/latest\/statistics\/stat_cox_regression_model.htm. Accessed Accessed May 22, 2023."},{"issue":"6","key":"10.1016\/j.ctarc.2023.100752_bib0033","doi-asserted-by":"crossref","first-page":"886","DOI":"10.21037\/tlcr.2019.11.16","article-title":"Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)","volume":"8","author":"Mandaliya","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"issue":"2","key":"10.1016\/j.ctarc.2023.100752_bib0034","article-title":"Desensitizing effect of cancer cachexia on immune checkpoint inhibitors in patients with advanced NSCLC","volume":"1","author":"Miyawaki","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"issue":"2","key":"10.1016\/j.ctarc.2023.100752_bib0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00262-021-02997-2","article-title":"Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab","volume":"71","author":"Jo","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.ctarc.2023.100752_bib0036","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001674","article-title":"Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer","volume":"8","author":"Johannet","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ctarc.2023.100752_bib0037","doi-asserted-by":"crossref","first-page":"8201","DOI":"10.2147\/CMAR.S210958","article-title":"Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients","volume":"11","author":"Magri","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"13","key":"10.1016\/j.ctarc.2023.100752_bib0038","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/0008-5472.CAN-14-2524","article-title":"Blocking tumor necrosis factor alpha enhances CD8 T-cell-dependent immunity in experimental melanoma","volume":"75","author":"Bertrand","year":"2015","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ctarc.2023.100752_bib0039","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.ctarc.2023.100752_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092200","article-title":"Association between body mass index and survival outcome in metastatic cancer patients treated by immunotherapy: analysis of a French Retrospective Cohort","volume":"13","author":"Collet","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0041","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.ctarc.2023.100752_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051230","article-title":"The effects of obesity on anti-cancer immunity and cancer immunotherapy","volume":"12","author":"Woodall","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"0 3","key":"10.1016\/j.ctarc.2023.100752_bib0043","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.12154","article-title":"The immune cells in adipose tissue","volume":"15 Suppl 3","author":"Ferrante","year":"2013","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"10.1016\/j.ctarc.2023.100752_bib0044","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.molcel.2021.03.037","article-title":"Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade","volume":"81","author":"Dai","year":"2021","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.21037\/tlcr-22-561","article-title":"The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review","volume":"12","author":"Morita-Tanaka","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"issue":"4","key":"10.1016\/j.ctarc.2023.100752_bib0046","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2023.100752_bib0047","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/SPC.0000000000000384","article-title":"Targeting the divergent TGFbeta superfamily cytokine MIC-1\/GDF15 for therapy of anorexia\/cachexia syndromes","volume":"12","author":"Tsai","year":"2018","journal-title":"Curr. Opin. Support Palliat. Care"},{"issue":"22","key":"10.1016\/j.ctarc.2023.100752_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225533","article-title":"Identification of potential biomarkers for cancer cachexia and anti-Fn14 therapy","volume":"14","author":"Cao","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0049","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jcsm.12351","article-title":"Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer","volume":"10","author":"Naito","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"issue":"21","key":"10.1016\/j.ctarc.2023.100752_bib0050","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1200\/JCO.20.00611","article-title":"Management of cancer cachexia: ASCO guideline","volume":"38","author":"Roeland","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100752_bib0051","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1186\/s12885-019-5762-6","article-title":"A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol","volume":"19","author":"Miura","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2023.100752_bib0052","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/bmjspcare-2017-001440","article-title":"Cancer cachexia: rationale for the MENAC (Multimodal-exercise, nutrition and anti-inflammatory medication for cachexia) trial","volume":"8","author":"Solheim","year":"2018","journal-title":"BMJ Support. Palliat. Care"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:35:12Z","timestamp":1762842912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294223000746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":52,"alternative-id":["S2468294223000746"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100752","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world prognostic utility of platelet lymphocyte ratio and nutritional status in first-line immunotherapy response in stage IV non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100752"}}